REGULATORY INFORMATION MANAGEMENT SYSTEM (RIMS) MARKET ANALYSIS

Regulatory Information Management System (RIMS) Market Report, by Application (Registration, Submission, Publishing, e-Archiving, and Others), by Component (Software and Services), by Deployment (On-Premise and Cloud Based), by Enterprise Size (SMEs and Large Enterprises), by End Use (Pharmaceutical Industry, Biotechnology Industry, and Clinical Research Organizations), and by Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Size, Share, Trends, and Forecast 2019 - 2027

Published In : Jul 2019
Code : CMI2827
Pages :180
Formats :
Excel and PDF
Industry : Information and Communication Technology

Regional Analysis

North America regulatory information management system (RIMS) market is expected to exhibit the highest CAGR over the forecast period

North America is anticipated to be dominant in the regulatory information management system (RIMS) market, due to high presence of pharmaceutical companies such as Amgen, GlaxoSmith, Novartis, Johnson & Johnson, and Gilead Sciences among others in countries such as the U.S. and Canada. Furthermore, according to a report by European Federation of Pharmaceutical Industries and Associations (EFPIA), in 2016, North America accounted for 49.0% of world pharmaceutical sales compared to 21.5% of Europe. According to IMS Health data (MIDAS May 2017), 64.7% of sales of new medicines launched during the period 2011-2016 were in the U.S. market, compared to 17.5% in the European market. This depicts the potential of North American as well as European markets for adoption of regulatory information management software. North America is followed by Asia Pacific in terms of market share in the regulatory information management system (RIMS) market, owing to growing pharmaceuticals industry in countries such as China and India. This is evident with the fact that, according to International Trade Administration, rising per capita income, aging population, greater access to healthcare, and regulatory reform are key drivers that will enhance the appeal of China\'s pharmaceutical market.